Global Medical Unit Head
Takeda Development Center Americas, Inc.
Disclosure(s): Takeda: Employee, Stocks/Bonds (Public Company)
Tien Bo is a graduate from the University of Connecticut School of Pharmacy. He has worked on teams that partner with investigators, regulators, patient advocacy groups and medical societies to develop new anti-infective drugs, which address significant unmet needs in order to improve patient outcomes. Maribavir (LIVTENCITY) is the latest anti-CMV drug approved.